高层震荡不断，博雅生物陷整合困局

Core Viewpoint - Frequent personnel changes at Boya Bio (300294.SZ) have raised concerns, particularly following the resignation of President Ren Hui after only 10 months in office, coinciding with a significant profit warning for 2025 [2][4]. Group 1: Management Changes - Ren Hui submitted his resignation from multiple positions, including President and legal representative, due to work changes, and will not hold any position in the company post-resignation [2]. - Ren Hui's tenure was notably short, as he was appointed in May 2025 and resigned in February 2026, marking him as the shortest-serving president in the company's history [4]. - The company has experienced three major leadership changes since 2021, indicating ongoing instability in management and challenges in integrating with the parent company, China Resources [5]. Group 2: Financial Performance - Boya Bio expects a revenue increase for 2025, projecting between 19.08 billion to 21.69 billion yuan, representing a growth of 10% to 25% year-on-year, primarily due to the acquisition of Green Cross Hong Kong Holdings [7]. - Despite revenue growth, the company anticipates a significant decline in net profit for 2025, forecasting a range of 1.05 billion to 1.37 billion yuan, a decrease of 65.62% to 73.55% compared to the previous year [8]. - The company is also expected to report a net loss of 7.5 million to 15 million yuan after excluding non-recurring gains, contrasting sharply with a profit of 302 million yuan in the same period of 2024 [8]. Group 3: Reasons for Profit Decline - The decline in profit is attributed to two main factors: a failed acquisition in the aesthetic medicine sector leading to substantial impairment losses, and pressures on the core blood products business due to regulatory changes and increased competition [9][10]. - The acquisition of Green Cross resulted in approximately 300 million yuan in impairment losses due to a downturn in the market for aesthetic products, which was seen as a significant investment misjudgment [9]. - The blood products segment is facing challenges from policy changes, leading to reduced clinical prescription volumes and a decline in overall gross margins, with a reported gross margin of 53.01% in the first half of 2025, down 14.02 percentage points year-on-year [10].